Cyclic GMP-specific phosphodiesterase 6B subunit (PDE6B)

Cyclic GMP-specific phosphodiesterase 6B subunit (PDE6B) is the beta catalytic subunit of the rod photoreceptor cGMP phosphodiesterase complex, which hydrolyzes cGMP to GMP and thus plays a critical role in retinal phototransduction[1][3][4][6]. The enzyme consists of two catalytic subunits (alpha and beta), together with two inhibitory gamma subunits, forming a heterotetrameric complex[2][6]. In rod photoreceptors, this complex sits at the heart of signal transduction, linking photon absorption to membrane hyperpolarization by regulating cGMP levels and thus the activity of cGMP-gated ion channels. PDE6B mutations disrupt this process, causing inherited forms of blindness. Several drugs designed to inhibit related PDE enzymes (like PDE5 for erectile dysfunction) can also weakly inhibit PDE6B, accounting for some visual side effects. PDE6B has a highly specialized function: it ensures precise control of cGMP metabolism in rods, and its structure and regulation have been extensively studied to understand vision and its diseases[1][2][4][6].

Other names

Rod cGMP-specific phosphodiesterase beta subunitPhosphodiesterase 6B, cGMP-specific, rod, betaPDE6B subunitPDE6 beta subunit

Competitive inhibition: drugs like sildenafil bind at the catalytic site, blocking cGMP hydrolysis; Allosteric modulation: certain inhibitors may induce conformational changes affecting catalytic efficiency and binding affinity for cGMP